| Literature DB >> 34809667 |
Antonio León-Jiménez1,2, José M Mánuel3,4, Marcial García-Rojo5,6, Marina G Pintado-Herrera7,8, José Antonio López-López7,9, Antonio Hidalgo-Molina10,5, Rafael García3,11, Pedro Muriel-Cueto5,6, Nieves Maira-González12, Daniel Del Castillo-Otero13, Francisco M Morales3,11.
Abstract
BACKGROUND: Engineered stone silicosis is an emerging disease in many countries worldwide produced by the inhalation of respirable dust of engineered stone. This silicosis has a high incidence among young workers, with a short latency period and greater aggressiveness than silicosis caused by natural materials. Although the silica content is very high and this is the key factor, it has been postulated that other constituents in engineered stones can influence the aggressiveness of the disease. Different samples of engineered stone countertops (fabricated by workers during the years prior to their diagnoses), as well as seven lung samples from exposed patients, were analyzed by multiple techniques.Entities:
Keywords: Aluminum; Artificial stone; Engineered stone; Quartz agglomerate; Silica; Silicosis; Volatile organic compounds
Mesh:
Substances:
Year: 2021 PMID: 34809667 PMCID: PMC8607701 DOI: 10.1186/s12989-021-00434-x
Source DB: PubMed Journal: Part Fibre Toxicol ISSN: 1743-8977 Impact factor: 9.400
Percentages of crystalline phases measured by XRD, atomic percentage of more often elements measured by XRF, and trace elemental analyses of specific metal species by ICP-MS
| Sample/method | M1 | M2 | M3 | M4 | M5 | M6 | M7 |
|---|---|---|---|---|---|---|---|
(cryst. %) | 2% Qu 98% Cri | 25% Qu 45% Cri 30% Alb | 100% Cri | 53% Qu 47% Cri | 56% Qu 44% Cri | 100% Qu | 100% Qu |
at. %* | 66.6 O 32.7 Si 0.5 Ti | 64.5 O 29.3 Si 3.3 Na 2.5 Al 0.2 Ti 0.1 Ca | 66.7 O 32.7 Si 0.6 Ti | 66.6 O 33.2 Si 0.1 Ti | 66.7 O 33.2 Si | 66.6 O 32.9 Si 0.3 Ti | 64.4 O 30.4 Si 3.3 Na 1.4 Ca 0.1 Mg |
| As | < 0.2 | < 0.2 | < 0.2 | < 0.2 | < 0.2 | < 0.2 | < 0.2 |
| Cd | 0.014 | 0.007 | 0.006 | < 0.003 | < 0.003 | 0.006 | 0.015 |
| Co | 42.2 | 62.4 | 29 | 127 | 102 | 75 | 71.3 |
| Cu | 4.93 | 13 | 5.30 | 98.1 | 50.2 | 58 | 96.0 |
| Ni | 5.21 | 9.1 | 3.21 | 21.6 | 16.4 | 12 | 12.4 |
| Pb | 1.1 | 1.95 | 1.2 | 0.53 | 0.66 | 2.21 | 409 |
| Zn | 3 | 20.5 | 6.56 | 256 | 59.5 | 228 | 312 |
| Ba | 24 | 16 | 25 | 11 | 10.3 | 13.4 | 262 |
| Mo | 0.222 | 0.251 | 0.204 | 0.385 | 7.44 | 0.280 | 0.413 |
| Sb | 0.151 | 0.150 | 0.154 | 0.150 | 0.170 | 0.154 | 0.413 |
| V | 0.971 | 1.72 | 0.870 | 0.592 | 208 | 0.830 | 2.20 |
| Ti | 8992 | 2861 | 9527 | 1067 | 691 | 4228 | 614 |
| Al | 1730 | 43,000 | 1622 | 1439 | 1900 | 1755 | 536 |
| Ca | 124 | 3188 | 115 | 152 | 169 | 143 | 45,546 |
| Na | 1913 | 30,250 | 2054 | 1216 | 1437 | 351 | 38,281 |
| Fe | 250 | 334 | 235 | 506 | 400 | 523 | 670 |
| W | 281 | 564 | 156 | 1221 | 1015 | 695 | 705 |
*Measurements < 0.1% have been discarded
**Limits of detection (mg/kg): As = 0.2, Cd = 0.003, Co = 0.230 Cu = 0.120, Ni = 0.084, Pb = 0.240, Zn = 0.580, Ba = 0.360, Mo = 0.130, Sb = 0.060, V = 0.130, Al = 100, Fe = 10, Ca = 20, Na = 110, Ti = 4, W = 30
Qu quartz, Cri cristobalite, Alb albite, XRD X-ray diffraction, XRF X-ray fluorescence, ICP Inductively coupled plasma
Concentrations of organic compounds (analyzed by GC–MS*)
| Sample | M1 | M2 | M3 | M4 | M5 | M6 | M7 |
|---|---|---|---|---|---|---|---|
| VOCs† (mg/kg) | STY: 0.81 BAL: Nt PA: Nt BA: Nt | STY: 0.79 BAL: Nt PA: Nt TCS: Nt | STY: 0.76 2EH: 0.87 PA2DM: Nt BAL: Nt PA: Nt TCS: Nt | STY: 0.83 mX: 0.71 TOL: 0.75 2EH: 0.9 TMA: Nt BAL: Nt PA: Nt TCS: Nt | STY: 0.81 mX: 0.73 TOL: 0.79 2EH: 0.88 BAL: Nt PA: Nt PA2DM: Nt DPG: Nt TCS: Nt | STY: 0.74 mX: 0.85 TOL: 0.80 BAL: Nt PA: Nt | STY: 0.88 mX: 0.71 TOL: 0.71 BAL: Nt PA: Nt BA: Nt |
| PAHs‡ (ng/g) | ACY: LOD ANT: ND BaA: ND CH: LOQ FLA: 9.2 FLU: 18.0 NAP: 10.8 PHE: 17.7 PYR: ND | ACY: LOD ANT: 18.5 BaA: LOQ CHR: LOQ FLA: 9.4 FLU: 18.8 NAP: 22.9 PHE: 20.8 PYR: LOQ | ACY: LOD ANT: LOD BaA: ND CHR: LOD FLA: ND FLU: 17.0 NAP: 14.4 PHE: 17.8 PYR: LOQ | ACY: LOD ANT: LOD BaA: ND CHR: LOQ FLA: ND FLU: 17.1 NAP: 15.3 PHE: 18.2 PYR: ND | ACY: LOD ANT: ND BaA: ND CHR: LOD FLA: ND FLU: ND NAP: 14.7 PHE: 19.1 PYR: LOQ | ACY: LOQ ANT: ND BaA: ND CHR: LOQ FLA: ND FLU: 16.5 NAP: 9.3 PHE: 21.6 PYR: ND | ACY: LOQ ANT: ND BaA: ND CHR: LOQ FLA: 9.5 FLU: 18.3 NAP: 39.3 PHE: 28.8 PYR: LOQ |
* GC–MS: Gas chromatography-mass spectrometry
† VOCs: Volatile organic compounds
‡ PAHs: Polycyclic aromatic hydrocarbons
2EH 2-ethyl-1-hexanol, BAL benzaldehyde, BA benzyl alcohol, PA2DM propanoic acid2,2 dimethyl, mX m-xylene, PA phthalic acid, TMA trimethylacetic acid, STY styrene, TOL toluene, DPG dipropylene glycol, TCS triclosan, ACY acenaphthylene, ANT anthracene, BaA benzanthracene, CHR chrysene, FLA fluoranthene, FLU fluorine, NAP naphthalene, PHE phenanthrene, PYR pyrene, Nt (nontarget) compounds detected (NIST Database) but not quantified, ND not detected, LOD limit of detection, LOQ limit of quantification
Sociodemographic and epidemiological data
| Patients | Age* | Year* | Duration of exposure (years) | Latency† | Smoking status*, ‡ | pack-years* | Type of lung biopsyξ |
|---|---|---|---|---|---|---|---|
| S1 | 26 | 2010 | 10 | 10 | S | 10 | TBB |
| S2 | 31 | 2010 | 15 | 16 | NS | - | TBB |
| S3 | 33 | 2010 | 10 | 11 | S | 1 | TBB |
| S4 | 37 | 2010 | 10 | 10 | NS | - | TBB |
| S5 | 37 | 2010 | 13 | 13 | S | 3 | TBB |
| S6 | 41 | 2018 | 15 | 18 | NS | - | VATS |
| S7 | 46 | 2016 | 23 | 23 | Ex | 25 | VATS |
* At the time of lung biopsy
Latency period (years) from onset of exposure to biopsy
S: Smoker. NS: Non-Smoker. Ex: Ex-smoker
ξTBB: Transbronchial biopsy. VATS: Video-assisted thoracoscopic surgery
Fig. 1Photographic image (a) and optical (b) and SEM (c) micrographs of sample S7, indicating an area surrounding a silicotic nodule close to the visceral pleura. In the SEM image, regions A to D are indicated. Histological overview of sample S3 showing the optical micrograph of a biopsy containing a well-defined nodule composed of histiocytic cells and fibroblasts, with indication of positions defined from A to D in the present study (d)
Fig. 2BSE-SEM micrograph (× 1000 magnification) from the center of a nodule in sample S3 (a), together with representative EDX map from regions A (e), B (f), C (g) and D (h) for Si (green) and Al (red) signals. Overlay of BSE-SEM images and EDX maps for Si (green) in sample S7 for regions A (i), B (j), C (k) and D (l)
EDX measured for atomic contents of Si, Al and others (C, O, N, Na, P, S) for regions A to D from all biopsy samples
| Sample | Region | Si (%) | Al (%) | Others (%) |
|---|---|---|---|---|
| A | 0.11 | 0.14 | 99.75 | |
| B | 0.08 | 0.03 | 99.91 | |
| C | 0.06 | 0.03 | 99.89 | |
| D | 0.03 | 0.01 | 99.96 | |
| A | 1.81 | 0.44 | 97.75 | |
| B | 0.44 | 0.14 | 9.42 | |
| C | 0.11 | 0.04 | 99.85 | |
| D | 0.02 | 0.04 | 99.94 | |
| A | 2.09 | 0.68 | 97.23 | |
| B | 1.32 | 0.24 | 98.44 | |
| C | 1.04 | 0.24 | 98.72 | |
| D | 0.08 | 0.07 | 99.85 | |
| A | 2.91 | 0.79 | 96.3 | |
| B | 0.83 | 0.18 | 98.99 | |
| C | 0.55 | 0.16 | 99.29 | |
| D | 0.12 | 0.10 | 99.78 | |
| A | 0.08 | 0.12 | 99.80 | |
| B | 0.05 | 0.11 | 99.84 | |
| C | 0.05 | 0.10 | 99.85 | |
| D | 0.02 | 0.02 | 99.96 | |
| A | 0.18 | 0.14 | 99.68 | |
| B | 0.08 | 0.43 | 99.49 | |
| C | 0.08 | 0.12 | 99.80 | |
| D | 0.00 | 0.00 | 100.00 | |
| A | 0.96 | 0.10 | 98.94 | |
| B | 0.08 | 0.09 | 99.83 | |
| C | 0.03 | 0.07 | 99.90 | |
| D | 0.04 | 0.01 | 99.95 |
Fig. 3EDX spectra normalized to the N peak for samples S2, S3 and S4, obtained from regions A (red), B (blue) and D (green) of a nodule for samples S3 (images (a) and (c)), S2 (b) and S4 (d)
Radiological classification and progression and their correspondent averaged Si and Al EDX detected percentages
| Patients | CRX ILO classification* | Main HRCT findings* | CRX ILO classification† | Main HRCT findings‡ | Si (%) | Al (%) | Progression rate per Year (PRY) |
|---|---|---|---|---|---|---|---|
| S1 | SS 2/3 q/t | A,B,F | FMP A | A,B,E,D,F | 0.07 | 0.0525 | 0.2727273 |
| S2 | PMF B | A,B,E | FMP C | A,B,E | 0.595 | 0.165 | 0.0909091 |
| S3 | SS 2/2 r/q | A,B, D | FMP B | A,B,D,E | 1.1325 | 0.3075 | 0.4545455 |
| S4 | SS 2/3 r/q | A,B,C | FMP C | A,B,D,E | 1.1025 | 0.3075 | 0.4545455 |
| S5 | SS 3/2 r/q | A | SS 3/3 r/q | A,B | 0.05 | 0.0875 | 0.0909091 |
| S6 | SS 1/2 q/q | A,B,C | SS 1/2 q/q | A,B | 0.085 | 0.1725 | 0 |
| S7 | SS 2/2 q/t | A, B, | SS 2/2 q/t | A, B, | 0.2775 | 0.0675 | 0 |
*At the time of lung biopsy. Last follow-up visit. Last HRCT. ξAveraged percentages of the EDX measurements at 4 regions (A to D) of each sample, obtained from the data in Table 4
SS Simple Silicosis, PMF Progressive Massive Fibrosis, A small nodular (round) opacities, B hilar and mediastinal lymphadenopathy, C ground-glass opacities, D Calcified lymphadenopathy, E Large opacities, F Interlobular septal thickening
Fig. 4Images of the countertops analyzed, the drill bit used, and the powder extracted and 4 XRD diagrams for 4 of the samples. Among them, the major crystalline phases of SiO2, i.e., quartz (Qu) and cristobalite (Cri), were detected, as well as minerals containing Na (AlSi3O8), i.e., albite (Alb). In the sample M4, approximately 2% of crystals (other) comprised 0.7% SiO2 tridymite, 0.4% TiO2 rutile, 0.35% Pb4BiVO8, and 0.2% intermetallic Sn3Ti5
Analytical parameters (limits of detection, limits of quantification and regression coefficient) for the proposed method
| Compound | Type | R2 | LOD | LOQ |
|---|---|---|---|---|
| Acenaphtene | PAH | 0.993 | 0.97 | 3.22 |
| Acenaphtylene | PAH | 0.999 | 0.78 | 2.59 |
| Anthracene | PAH | 0.991 | 0.86 | 2.85 |
| Benz(a)anthracene | PAH | 0.985 | 0.48 | 1.62 |
| Benzo(a)pyrene | PAH | 0.985 | 1.93 | 6.44 |
| Benzo(b + k)fluoranthene | PAH | 0.987 | 1.39 | 4.63 |
| Benzo(ghi)perylene | PAH | 0.988 | 4.44 | 14.80 |
| Chrysene | PAH | 0.991 | 0.44 | 1.48 |
| Dibenz(ah)anthracene | PAH | 0.993 | 4.44 | 14.80 |
| Fluoranthene | PAH | 0.999 | 0.39 | 1.31 |
| Fluorene | PAH | 0.996 | 0.48 | 1.61 |
| Indene(123-cd)pyrene | PAH | 0.985 | 8.02 | 26.73 |
| Naphthalene | PAH | 0.996 | 2.48 | 8.25 |
| Phenanthrene | PAH | 0.997 | 0.91 | 3.04 |
| Pyrene | PAH | 0.998 | 0.37 | 1.22 |
| PCB101 | PCB | 0.993 | 0.47 | 1.58 |
| PCB138 | PCB | 0.989 | 0.98 | 3.28 |
| PCB153 | PCB | 0.995 | 1.23 | 4.11 |
| PCB180 | PCB | 0.990 | 1.65 | 5.51 |
| PCB28 | PCB | 0.989 | 0.95 | 3.16 |
| PCB52 | PCB | 0.990 | 0.36 | 1.20 |
| 1Hexanol 2 ethyl | COV | 0.991 | 8.72 | 15.3 |
| Styrene | COV | 0.989 | 4.31 | 12.1 |
| Toluene | COV | 0.994 | 4.47 | 13.3 |
| Ethylbenzene | COV | 0.995 | 3.14 | 11.2 |
| 124 Trimethylbenzene | COV | 0.995 | 2.72 | 9.25 |
| 1Methoxy 2 propanol | COV | 0.987 | 4.65 | 15.68 |
| n-butylacetate | COV | 0.989 | 6.27 | 21.29 |
| m-xylene | COV | 0.985 | 3.32 | 10.35 |
| p-xylene | COV | 0.986 | 3.32 | 10.35 |